Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4368-4375

  Kishi, Kentaro ^a   Doki, Yuichiro ^b   Yano, Masahiko ^a   Yasuda, Takushi ^a   Fujiwara, Yoshiyuki ^a   Takiguchi, Syuji ^a   Kim, Sontae ^a   Higuchi, Ichiro ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PROTEIN MLH1; PROTEIN P53;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PATHOLOGY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RESISTANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE PAIR MISMATCH; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CISPLATIN; COMBINED MODALITY THERAPY; DOWN-REGULATION; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141995086     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fink, D., Aebi, S., and Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4: 1-6, 1998.
2. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M., and Wang, J. Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (Lond.), 399: 806-809, 1999.
3. Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (Lond.), 368: 258-261, 1994.
4. Lu, S. L., Kawabata, M., Imamura, T., Akiyama, Y., Nomizu, T., Miyazono, K., and Yuasa, Y. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat. Genet., 19: 17-18, 1998.
5. Cui, H., Horon, I. L., Ohlsson, R., Hamilton, S. R., and Feinberg, A. P. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med., 4: 1276-1280, 1998.
6. Fishel, R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res., 61: 7369-7374, 2001.
7. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
8. Drummond, J. T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 271: 19645-19648, 1996.
9. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
10. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., and Boothman, D. A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res., 61: 5193-5201, 2001.
11. Samimi, G., Fink, D., Varki, N. M., Husain, A., Hoskins, W. J., Alberts, D. S., and Howell, S. B. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res., 6: 1415-1421, 2000.
12. Mackay, H. J., Cameron, D., Rahilly, M., Mackean, M. J., Paul, J., Kaye, S. B., and Brown, R. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J. Clin. Oncol., 18: 87-93, 2000.
13. Watanabe, Y., Koi, M., Hemmi, H., Hoshai, H., and Noda, K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br. J. Cancer, 85: 1064-1069, 2001.
14. Doki, Y., Ishikawa, O., Mano, M., Hiratsuka, M., Sasaki, Y., Kameyama, M., Ohigashi, H., Murata, K., Yamada, T., Miyashiro, I., Yokoyama, S., Ishiguro, S., and Imaoka, S. Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J. Surg. Res., 107: 75-81, 2002.
15. Miyata, H., Doki, Y., Shiozaki, H., Inoue, M., Yano, M., Fujiwara, Y., Yamamoto, H., Nishioka, K., Kishi, K., and Monden, M. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin. Cancer Res., 6: 4859-4865, 2000.
16. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. (Bethesda), 92: 205-216, 2000.
17. Japanese Society for Esophageal Diseases. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, Ed. 9, pp. 55-58. Tokyo: Kanehara, 1999.
18. Miyakura, Y., Sugano, K., Konishi, F., Ichikawa, A., Maekawa, M., Shitoh, K., Igarashi, S., Kotake, K., Koyama, Y., and Nagai, H. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology, 121: 1300-1309, 2001.
19. Fleisher, A. S., Esteller, M., Tamura, G., Rashid, A., Stine, O. C., Yin, J., Zou, T. T., Abraham, J. M., Kong, D., Nishizuka, S., James, S. P., Wilson, K. T., Herman, J. G., and Meltzer, S. J. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene, 20: 329-335, 2001.
20. Eads, C. A., Lord, R. V., Wickramasinghe, K., Long, T. I., Kurumboor, S. K., Bernstein, L., Peters, J. H., DeMeester, S. R., DeMeester, T. R., Skinner, K. A., and Laird, P. W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res., 61: 3410-3418, 2001.
21. Tomita, S., Deguchi, S., Miyaguni, T., Muto, Y., Tamamoto, T., and Toda, T. Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res. Treat., 53: 33-39, 1999.
22. Hayami, Y., Komatsu, H., Iida, S., Utsunomiya, A., Hanada, S., Hua, X. J., Huiping, N., Harada, S., Tsuboi, K., Banno, S., Wakita, A., Kato, T., and Ueda, R. Microsatellite instability as a potential marker for poor prognosis in adult T cell leukemia/lymphoma. Leuk. Lymphoma, 32: 345-349, 1999.
23. Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., and Anthoney, D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997.
24. Paulovich, A. G., Margulies, R. U., Garvik, B. M., and Hartwell, L. H. RAD9, RAD17, and RAD24 are required for S phase regulation in Saccharomyces cerevisiae in response to DNA damage. Genetics, 145: 45-62, 1997.
25. Vikhanskaya, F., Colella, G., Valenti, M., Parodi, S., D'Incalci, M., and Broggini, M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin. Cancer Res., 5: 937-941, 1999.
26. Branch, P., Masson, M., Aquilina, G., Bignami, M., and Karran, P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene, 19: 3138-3145, 2000.
27. Liu, L., Schwartz, S., Davis, B. M., and Gerson, S. L. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res., 62: 3070-3076, 2002.
28. Chen, S., Bigner, S. H., and Modrich, P. High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6. Proc. Natl. Acad. Sci. USA, 98: 13802-13807, 2001.
29. Strathdee, G., Sansom, O. J., Sim, A., Clarke, A. R., and Brown, R. A role for mismatch repair in control of DNA ploidy following DNA damage. Oncogene, 20: 1923-1927, 2001.
30. Jacob, S., Aguado, M., Fallik, D., and Praz, F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res., 61: 6555-6562, 2001.
31. Yan, T., Schupp, J. E., Hwang, H. S., Wagner, M. W., Berry, S. E., Strickfaden, S., Veigl, M. L., Sedwick, W. D., Boothman, D. A., and Kinsella, T. J. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation. Cancer Res., 61: 8290-8297, 2001.
32. Davis, T. W., Wilson-Van Patten, C., Meyers, M., Kunugi, K. A., Cuthill, S., Reznikoff, C., Garces, C., Boland, C. R., Kinsella, T. J., Fishel, R., and Boothman, D. A. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res., 58: 767-778, 1998.